OmRx Oncology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

OmRx Oncology is a private, pre-revenue biotech founded in 2019 with a mission to democratize access to cancer immunotherapy through oral small molecule checkpoint inhibitors. Its core strategy involves in-licensing and developing Phase 2-ready asset OX-4224, acquired from Gilead Sciences, targeting both underserved markets and advanced combination regimens in developed regions. The company aims to address significant unmet needs in global oncology by offering a lower-cost, orally administered alternative to intravenous antibody therapies, with a focus on improving accessibility and safety.

Oncology

Technology Platform

Oral small molecule immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway, designed for lower cost, simplified logistics, and improved safety in combinations versus antibody-based therapies.

Opportunities

A massive global 'access gap' exists for checkpoint inhibitors in developing regions due to high cost and IV administration; OX-4224 as an oral, lower-cost therapy is positioned to address this.

In developed markets, the drug's pharmacokinetic profile enables the development of safer, all-oral combination regimens with targeted therapies, addressing a key unmet need in oncology treatment paradigms.

Risk Factors

High clinical risk as the company's value is tied to a single, unproven Phase 2 asset.

Significant commercial risk in displacing entrenched antibody therapies in developed markets and in building distribution in complex emerging economies.

Financial risk is acute as a pre-revenue company requiring substantial capital to complete late-stage trials and launch globally.

Competitive Landscape

OmRx faces intense competition from dominant, validated IV antibody therapies (e.g., Merck's Keytruda, Bristol Myers Squibb's Opdivo) with extensive clinical data and commercial infrastructure. It also competes with other companies developing oral small molecule checkpoint inhibitors, though none are yet approved. Its primary competitive edge is not head-to-head efficacy, but rather superior accessibility, cost, and potential safety in combinations.

More companies in Small Molecule Drugs →More companies in United States →